# Melanotans

Sonoran UV Biology · Clinical & Regulatory Field Report

**Directory:** [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Scenesse](/afamelanotide-scenesse) · [Vyleesi](/bremelanotide-vyleesi) · [Imcivree](/setmelanotide-imcivree) · [Online Market](/melanotan-online-market) · [Case Reports](/case-reports-and-safety) · [Regulators](/regulatory-warnings) · [References](/references) · [About](/about)

**Regulatory Records · Dated Verbatim Statements Across Six Jurisdictions (2011–2026)** · Dispatch 08 · Regulatory Ledger

---

[Melanotans](/) / Regulatory Warnings

# Regulatory records from six jurisdictions, including the U.S. FDA and HHS

Online summaries frequently blur prescription approvals, compounding withdrawals, and national enforcement statements. This ledger quotes official documents from six jurisdictions verbatim with exact dates.

**Field Record 10 · Six-Jurisdiction Archive:** Every regulatory quotation on this page is copied verbatim from the official opened record with exact dates and full operative sentences.

## United States: Prescription drug labels and 2026 compounding records

### U.S. FDA Prescribing Records (2019–2026)

- **Afamelanotide (Scenesse):** [Marketing Approval Date: 10/08/2019](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=263208); [Prescribing Information (Revised: 10/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf): "SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)."
- **Bremelanotide (Vyleesi):** [Approval Letter (06/21/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf) and [Prescribing Information (Revised: 6/2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf): "VYLEESI is a melanocortin receptor agonist indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance." "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men." "VYLEESI is not indicated to enhance sexual performance." "VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease."
- **Setmelanotide (Imcivree):** [Prescribing Information (Initial U.S. Approval: 2020; Revised: 03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf): "IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged (1): 4 years and older with acquired hypothalamic obesity (HO). 2 years and older with Bardet-Biedl syndrome (BBS). 2 years and older with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)." "IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign. Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity."

### 1. U.S. FDA Bulk Drug Substances Safety Page — Content current as of: 04/22/2026

> "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators."
>
> "Melanotan II: Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism."

Source: [FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks).

### 2. U.S. HHS Draft 503A Policy — October 30, 2026 (91 FR 68526)

> "HHS is announcing the availability of a draft 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.'" "The draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances does not establish any rights for any person and is not binding on HHS or the public."
>
> "Therefore, to expand and improve patient access while FDA reviews these substances, in the circumstances below, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A."

**Appendix A heading:** Appendix A. List of Peptide Bulk Drug Substances Addressed by HHS Interim Enforcement Policy Regarding 503A Compounding

**Listed substances (6):** 1. BPC-157 · 2. Epitalon · 3. KPV · 4. MOTS-c · 5. Semax · 6. TB-500 (Melanotan II is not listed).

Sources: [91 FR 68526 (Oct 30, 2026)](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances); [HHS Draft Policy PDF](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf).

## European Union: EMA assessment reports

### European Medicines Agency (EMA) — EPAR Records

> "The European Commission granted a marketing authorisation valid throughout the European Union for Scenesse on 22 December 2014." "Scenesse has been authorised under 'exceptional circumstances'. This is because it has not been possible to obtain complete information about the benefits of Scenesse, in part due to the rarity of the disease." "Scenesse must not be used in patients with reduced liver or kidney function."
>
> "Imcivree received a marketing authorisation valid throughout the EU on 16 July 2021." "Imcivree is a medicine used to treat obesity and help control hunger caused by certain conditions that affect how the brain controls feelings of hunger. It is used: in adults and children aged 4 years and older with acquired hypothalamic obesity (aHO), a condition that occurs when the hypothalamus (a part of the brain) does not work properly, either following an injury or because of an underlying disease; in adults and children aged 2 years and older who have pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency; these genetic conditions result from changes (mutations) in both copies of the genes responsible for making POMC, PCSK1 or LEPR; in adults and children aged 2 years and older with a genetic condition called Bardet Biedl syndrome (BBS)."

Sources: [EMA Scenesse EPAR (updated 07/10/2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse); [EMA Imcivree EPAR (Last updated: 27/05/2026; procedure dated 30/04/2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree).

## United Kingdom: MHRA classification and Yellow Card record

### UK MHRA — FOI 24/274, Dated 17th April 2024

> "Products containing Melanotan II are classified as medicines if they are injectable or pens. If a product contains Melanotan II and is in the form of a nasal spray, it will be determined as a medicine only if sold with claims to treat or prevent disease."
>
> "It is important to note that the sale, supply and advertising of unauthorised medicines is not permitted under the Human Medicines Regulations."
>
> "Following a search of our database, 16 UK spontaneous suspected Adverse Drug Reaction (ADR) reports for Melanotan II were received between the 1st January 2012 and the 31st December 2022." "Please note that the inclusion of a report on our ADR database does not necessarily mean that the events were caused by the product."
>
> "However, the MHRA has repeatedly taken action to remove Melanotan products from the market for over 10 years and will continue to do so where products fall within the definition of a medicinal product"

Source: [UK MHRA FOI 24/274 (17 April 2024)](https://assets.publishing.service.gov.uk/media/669fbd3aa3c2a28abb50d55a/Final_Redaction_FOI_24_274.pdf).

## Australia, New Zealand, and Denmark

### Australia TGA — 24 January 2025

> "Melanotan is not approved for sale or use as a tanning agent in Australia. These tanning agents haven’t been assessed for their quality or safety."
>
> "It is illegal to supply tanning products containing melanotan without a doctor’s prescription. These restrictions apply regardless of whether it is a spray, a tablet, an injection, a cream or in any other form."
>
> "It is also illegal to advertise melanotan to the Australian public. This includes promotion by social media influencers." "In 2023-24, the TGA requested the removal of over 4,800 unlawful advertisements of therapeutic goods from various digital platforms (including social media platforms)."

Source: [TGA (24 January 2025)](https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan).

### New Zealand Medsafe — 21 May 2026

> "Medsafe has NOT assessed these products for quality, safety or efficacy. They are unapproved products."
>
> "Many sellers label these products as 'for research purposes only'. This wording has no legal effect and does not permit sale, supply, or use in people."

Source: [Medsafe (21 May 2026)](https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp), listing `melanotan II` among advertised online peptides.

### Denmark — Danish Medicines Agency, 20 June 2011

> "The Danish Medicines Agency repeats its warning against using the illegal product Melanotan because its effect is not documented and because of the absence of studies of its potential side effects."
>
> "The product is not authorised in Denmark, Europe or the United States." "In 2008, the Danish Medicines Agency issued a warning about online sale of Melanotan."

Source: [Danish Medicines Agency (20 June 2011)](https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/warnings-against-products/warning-against-the-tanning-product-melanotan/).

---

## Six-Jurisdiction Index

- **United States:** FDA prescribing labels & orphan/approval records (2019–03/2026); FDA bulk substances page (04/22/2026); HHS draft policy (10/30/2026, `91 FR 68526`)
- **European Union:** EMA Scenesse EPAR (updated 07/10/2026) & Imcivree EPAR (updated 27/05/2026)
- **United Kingdom:** MHRA `FOI 24/274` (17 April 2024)
- **Australia & New Zealand:** TGA public warning (24 January 2025); Medsafe consumer advisory (21 May 2026)
- **Denmark:** Danish Medicines Agency warning (20 June 2011; prior 2008 notice)

### Inspect Related Dispatches
- [Full 54-Source Bibliography](/references)
- [06. Online Melanotan I & II: Lab Assays](/melanotan-online-market)
- [07. Case Reports, Moles & Causality](/case-reports-and-safety)
- [05. Setmelanotide (Imcivree)](/setmelanotide-imcivree)

- Previous Dispatch · 07: [Case Reports & Safety Audit](/case-reports-and-safety)
- Complete Archive: [54 Cited Sources](/references)

---

**Melanotans** is an independent educational pharmacology field report on melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II—not a laboratory, manufacturer, clinic, pharmacy, telehealth service, or seller, and never medical advice.

- Plain-text edition: [regulatory-warnings.md](/regulatory-warnings.md) · Full bibliography: [Primary Source Ledger](/references)
- Pathway & Prescription Medicines: [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Afamelanotide (Scenesse)](/afamelanotide-scenesse) · [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi) · [Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- Online Market, Safety & Charter: [Online Market & Lab Assays](/melanotan-online-market) · [Case Reports & Safety](/case-reports-and-safety) · [Regulatory Warnings](/regulatory-warnings) · [References](/references) · [About](/about) · [Contact](/contact)
